|
|
 |
|
Viewing report
|
|
|
|
The Market for Pharmaceuticals in Brazil, Russia, India & China 2008
Espicom Business Intelligence Ltd, Jan 2008, Pages: 340
Evaluate the status, opportunities and threats for pharmaceutical companies in Brazil, Russia, India and China now and in the future. Market forecasts to 2013 are provided, plus free quarterly-updated market outlook reports on each country, keeping you up to date with developments for a full year.
Many are concerned that a potential global economic downturn could blunt the rapid growth in the BRIC countries. Is this a time of exciting opportunity or commercial danger for pharmaceutical manufacturers? This report separates the fact from the fiction and is essential in making sound, impartial business judgements.
This insightful report provides:
- 5-year forecasts to 2013 and market valuations for each market
- A detailed analysis of the health structure, funding, service and outlook
- Quarterly updated reports of key developments in the market
These leading emerging and rapidly-growing economies represented a total market of 2.76 billion people and a combined GDP of US$6.1 trillion in 2007. But where do commercial opportunities exist for pharmaceutical companies now, and what are the future prospects?
Putting things in perspective
The BRIC countries’ pharmaceutical markets are currently valued at US$54.9 billion. This is a large sum of money, but is collectively lower than found in leading markets such as the USA and Japan. Growth rates, ranging from 5% in Brazil to 15% in Russia are impressive, but the low starting point – along with a range of other operational issues – means companies must be targeted in the opportunities they pursue.
Opportunities do exist
There are, of course, wide regional differences in expenditure levels within the BRIC countries, far more so than in developed countries where health systems have evolved to provide a more uniform level of coverage. All four countries have a relatively wealthy urban population with a far greater spending power than their respective national average. In the case of China and India, these urban populations have grown rapidly, and number hundreds of millions. The challenge for these countries is to extend this level of wealth to the rest of the population, in order that better levels of healthcare become affordable.
A long haul
This is evolution not revolution, and change will be incremental. Short-term opportunities exist in meeting the health demands of the burgeoning middle classes, and future prospects are bright, where steady growth in BRIC markets will erode commercial differences with the established markets in North America, Japan and Europe.
Current and accurate decision support information is vital
For each country there is a comprehensive examination of the market for pharmaceuticals which covers all aspects of the operating environment from the regulatory situation through health provision/expenditure to domestic production. Importantly, each market evaluation includes 5-year growth forecasts and SWOT analysis. An additional benefit - at no extra cost – is that concise quarterly-updated outlook reports are included in the price.
Customers who bought this item also bought
The Market for Medical Devices in Brazil, Russia, India & China 2008
Barr Pharmaceuticals Inc Deals Briefing
Watson Pharmaceuticals Inc Deals Briefing
Indian Pharmaceuticals Industry Report
Pharmaceuticals: Global Industry Guide
Pharmaceuticals in China
Cough, Cold and Allergy (Hay Fever) Remedies in India
Global forecast market size for mobile communications services in each of seven key emerging markets ( Argentina, Brazil, China, India, Mexico, Russia and Turkey ), expressed as number of subscribers in 2000 and 2003, with percent market penetration
|
|
|
|
